The subject-matter of the contract is the supply of trastuzumab and rituximab. The description of the supplies requested shall be included in the procurement documents. The establishments which will be parties to the contracts to be concluded at the end of the procedure are: - the Centre Hospitalier Émile Mayrisch (CHEM), - the Centre Hospitalier de Luxembourg (CHL), - the Centre Hospitalier du Nord (CHdN), and - the Robert Schuman Hospitals (HRS).

Trastuzumab intravenous injectable form, 420 mg.

Rituximab, intravenous injectable form, 500 mg.